A share price of Ascendis Pharma A/S ADR [ASND] is currently trading at $210.49, up 0.45%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ASND shares have gain 2.98% over the last week, with a monthly amount glided 4.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on November 18, 2025, when Wolfe Research initiated its Peer Perform rating and assigned the stock a price target of $255. Previously, Raymond James started tracking the stock with Strong Buy rating on October 17, 2025, and set its price target to $271. Morgan Stanley upgraded its rating to an Overweight but stick to its price target of $250 on May 05, 2025. RBC Capital Mkts initiated its recommendation with an Outperform and recommended $205 as its price target on April 16, 2025. UBS started tracking with a Buy rating for this stock on January 07, 2025, and assigned it a price target of $196. In a note dated September 05, 2024, Oppenheimer upgraded an Outperform rating on this stock but restated the target price of $180.
Ascendis Pharma A/S ADR experienced fluctuations in its stock price throughout the past year between $118.03 and $223.18. Currently, Wall Street analysts expect the stock to reach $242 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $210.49 at the most recent close of the market. An investor can expect a potential return of 14.97% based on the average ASND price forecast.
Analyzing the ASND fundamentals
Trailing Twelve Months sales for Ascendis Pharma A/S ADR [NASDAQ:ASND] were 720.68M which represents 292.94% growth. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.54%, and Net Profit Margin reading is -0.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is 1.87 and Total Capital is -1.66. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -4.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 206.93 points at the first support level, and at 203.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 212.90, and for the 2nd resistance point, it is at 215.31.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ascendis Pharma A/S ADR [NASDAQ:ASND] is 1.03. Also, the Quick Ratio is 0.73, while the Cash Ratio stands at 0.53. Considering the valuation of this stock, the price to sales ratio is 17.85.
Transactions by insiders
Recent insider trading involved JENSEN FLEMMING STEEN, Officer, that happened on Sep 09 ’25 when 5000.0 shares were purchased. Officer, JENSEN MICHAEL WOLFF completed a deal on Aug 29 ’25 to buy 5000.0 shares. Meanwhile, Officer PEDERSEN ANNI LOTTE KIRSTINE S bought 3036.0 shares on Aug 27 ’25.
